| Stage | HALO | % of rev | GMED | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $493M | 100.00% | $764M | 100.00% | GMED ×1.55 |
| Gross profit | $410M | 83.27% | $531M | 69.50% | HALO +13.8pp |
| Operating income | $295M | 59.83% | $178M | 23.25% | HALO +36.6pp |
| Pre-tax income | $291M | 58.95% | $183M | 24.00% | HALO +35.0pp |
| Net income | $247M | 50.11% | $141M | 18.48% | HALO +31.6pp |
| Stage | HALO | GMED | Gap · A − B |
|---|---|---|---|
| Revenue | $493M100.00% | $764M100.00% | GMED ×1.55 |
| Gross profit | 83.27%$410M | 69.50%$531M | HALO +13.8pp |
| Operating income | 59.83%$295M | 23.25%$178M | HALO +36.6pp |
| Pre-tax income | 58.95%$291M | 24.00%$183M | HALO +35.0pp |
| Net income |
| 50.11%$247M |
| 18.48%$141M |
| HALO +31.6pp |
No disclosed counterparties: GMED.
None